MME and renal cell adenocarcinoma: Based on this result, CK (AE1/AE3), CD10, and EpCAM were chosen as the potential immunomarkers for CTC-based diagnosing for RCC (Fig. 6), and these markers were applied to clinical samples from patient with RCC.